Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while iShares Broad USD Investment Grade Corporate Bond trades at $50.21. The key difference: Citius Pharmaceuticals Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| CTXR | USIG | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $52.69 |
52-Week Low | $0.48 | $50.18 |
Enterprise Value | $16.23M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
